एम्फेटामाइन के इंटरैक्शन

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Excessive Use of Arformoterol Tartrate Inhalation Solution and Use with Other Long-Acting Beta2-Agonists Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (आरफॉर्मोटेरोल लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

DO NOT EXCEED RECOMMENDED DOSE Fatalities have been reported in association with excessive use of inhaled products containing sympathomimetic amines and with the home use of nebulizers. (इप्राट्रोपियम और सैल्बुटामोल लेबल, चेतावनियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (कोकेन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

• Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (ज़िप्रासिडोन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (टरब्यूटालिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (ड्रोनाबिनोल लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics. (पिमोज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (फॉर्मोटेरोल लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (फ्लुटिकासोन और सैल्मेटेरोल लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, चेतावनियां और सावधानियां)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (लियोथायरोनिन लेबल, बॉक्स्ड चेतावनी)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (लेवोथायरोक्सिन और लियोथायरोनिन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (लेवोसैल्बुटामोल लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (सैल्बुटामोल लेबल, चेतावनियां और सावधानियां)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (सैल्मेटेरोल लेबल, चेतावनियां और सावधानियां)

Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )]. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (इंसुलिन एस्पार्ट लेबल, दवाओं के इंटरैक्शन)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (इंसुलिन ग्लार्जिन लेबल, दवाओं के इंटरैक्शन)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (इंसुलिन डेग्लुडेक लेबल, दवाओं के इंटरैक्शन)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (इंसुलिन डेटेमिर लेबल, दवाओं के इंटरैक्शन)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (इंसुलिन लिस्प्रो लेबल, दवाओं के इंटरैक्शन)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (एक्लिडिनियम लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (एलोग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (एसिटाज़ोलामाइड लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (एस्टाज़ोलम लेबल, चेतावनियां)

Sympathomimetic drugs: Dose adjustment needed (7) (एस्मोलोल लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ऑक्साज़ेपाम लेबल, चेतावनियां)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (केटामिन लेबल, चेतावनियां और सावधानियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोनाज़ेपाम लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड और क्लिडिनियम लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोराज़ेपेट लेबल, चेतावनियां)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (ग्लिपिज़ाइड लेबल, दवाओं के इंटरैक्शन)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. (ग्वानफेसिन लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (टेमाज़ेपाम लेबल, चेतावनियां)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (टोलकैपोन लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (डायज़ेपाम लेबल, चेतावनियां)

Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (डिगॉक्सिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (डॉक्साप्राम लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (नेटेग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Sympathomimetics Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. (मेटोलाज़ोन लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (लेवोथायरोक्सिन लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (सोटालोल लेबल, दवाओं के इंटरैक्शन)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Careful observation is required when amantadine hydrochloride is administered concurrently with central nervous system stimulants. (अमैंटाडिन लेबल, दवाओं के इंटरैक्शन)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (इप्राट्रोपियम लेबल, दवाओं के इंटरैक्शन)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (एकार्बोज़ लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

…occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (एम्पाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (एसिब्यूटोलोल लेबल, चेतावनियां)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (ग्लिपिज़ाइड और मेटफॉर्मिन लेबल, सावधानियां)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (ग्लिबेनक्लामाइड लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (ग्लिबेनक्लामाइड और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (टियागाबिन लेबल, चेतावनियां)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (डैपाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (पियोग्लिटाज़ोन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (ब्रोमोक्रिप्टिन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (रेगुलर इंसुलिन (ह्यूमन) लेबल, दवाओं के इंटरैक्शन)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (रैमेल्टियॉन लेबल, चेतावनियां और सावधानियां)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (लिनाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods. (लेबेटालोल लेबल, दवाओं के इंटरैक्शन)

…occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (सिटाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (सैक्साग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (एम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)